Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)

About this study

Last updated on

This study is for people with:Multiple Sclerosis
Intervention being studied:MD1003 100mg capsule, PLACEBO (drug)
Purpose:
Treatment
A study testing a potential treatment for a disease or condition.
Sponsored by:MedDay Pharmaceuticals SA
Number of participants:600 participants
Unique study IDNCT02936037

How to apply

Find a study site convenient for you below, then email yourself the contact details and next steps.

Choose a site

Participation requirements

Open toboth females and males
Open to people aged18 to 65 years old

There are no locations currently recruiting for this study

By leaving your email you are accepting our terms & conditions and privacy policy